Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

32.5K
Overview
32.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Cross-reactivity00:42

Cross-reactivity

33.2K
Overview
33.2K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

21
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
21
Hypersensitivities01:30

Hypersensitivities

7.8K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Decalogue of the Declaration of Salamanca: Advancing Undergraduate Education in Allergy and Clinical Immunology Across Europe.

Allergy·2026
Same authorSame journal

Route of Allergen Immunotherapy: A Global Look Into Physicians' Motivations.

Allergy·2026
Same author

Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review.

Clinical and translational allergy·2026
Same author

Leveraging Artificial Intelligence in Allergy, Asthma, and Immunology With Environmental Exposures.

Allergy·2026
Same author

Algorithms of Patient Selection for Allergen Immunotherapy.

Allergy·2026

Related Experiment Video

Updated: Feb 18, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.0K

Perspectives in allergen immunotherapy: 2017 and beyond.

O Pfaar1,2, S Bonini3,4, V Cardona5

  • 1Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Allergy
|November 25, 2017
PubMed
Summary

Experts discussed advances in allergen immunotherapy (AIT), including personalized treatments and regulatory challenges. They highlighted unmet needs and potential solutions for future AIT development and standardized allergy treatment practices.

Keywords:
Allergen immunotherapybiomarkersin vivo diagnosticslegislationprecision medicine

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Related Experiment Videos

Last Updated: Feb 18, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.0K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Area of Science:

  • Allergy and Immunology
  • Pharmacology
  • Regulatory Science

Background:

  • The Future of the Allergists and Specific Immunotherapy (FASIT) workshop convenes global experts to discuss allergen immunotherapy (AIT).
  • The 2017 workshop focused on recent advances and regulatory considerations in AIT.

Purpose of the Study:

  • To review current developments and future directions in allergen immunotherapy.
  • To identify unmet needs and propose solutions in AIT research and clinical practice.
  • To discuss the impact of regulatory changes on AIT availability and research.

Main Methods:

  • The content is based on discussions from the FASIT workshop held in February 2017.
  • Key topics included personalized AIT, novel adjuvants, delivery systems, new molecules, vaccines, regulatory impacts, clinical trial challenges, and pediatric considerations.
  • Expert panel discussions and insights were synthesized for this review.

Main Results:

  • Advances in personalized AIT, adjuvants, delivery systems, and vaccine development were explored.
  • Regulatory challenges, including the impact of European Directive 2001/83, were discussed.
  • The role of allergen exposure chambers and pediatric AIT studies were highlighted.

Conclusions:

  • The review identifies significant unmet needs in allergen immunotherapy research and clinical application.
  • Potential solutions and future directions for AIT development and standardization are proposed.
  • Upcoming EAACI guidelines are expected to standardize allergy treatment practices.